Clinical Trial Update: A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating SSR411298 as an adjunctive treatment for persistent cancer pain has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breakthrough Cancer Pain
• Cancer Pain

Drugs mentioned

• SSR411298

Snippet

Sponsor: Sanofi | Conditions: Pain, Breakthrough Cancer Pain | Phase 2 | Status: TERMINATED